5David PerezPresident
Blood Management Company

BloodManagementCompany© Terumo Corporation

Business Overview: Blood Management Company

BloodCentersBloodManagementCompany

TherapeuticSystemsCellProcessing

FY15 Sales

Major Product Categories

77B JPY•Automated Collections•Whole Blood Core
•Whole Blood Automation•Pathogen Reduction Technologies•Software•Solutions

20B JPY•Therapeutic Apheresis•Cell Collections•Extracorporeal Photopheresis

8B JPY•Cell Therapy Technologies•Point-of-Care Cell Therapies(Harvest)

105B JPY© Terumo Corporation

Dec 12, 2016

1/17

History of Long-Term Profitable Growth
Annual Blood Management Company Sales
Stable Growth

Rapid GlobalMarket Expansion

Industry
Consolidation andTransformation

Return to Growthin Existing andNew Markets

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

Sales prior to 2011 represent the pro forma combined pre-acquisition sales of Terumo Transfusion and CaridianBCT.
All historical sales are at actual FX rates and forward-looking sales are at 2016 Plan FX rates.

© Terumo Corporation

Dec 12, 2016

2/17

New Clinical Horizons
Shifting our Focus from Products to Disease-States and Medical Specialties

ONCOLOGY

Product

AUTOIMMUNEDISORDERS

DiseaseHEMATOLOGY© Terumo CorporationREGENERATIVEMEDICINE

Dec 12, 2016

3/17

Solutions to Drive Standards of Care
Oncology

Oncology• Spectra Optia System• Supporting patients through bloodcancer therapies and treatments
while driving to personalized cures• Quantum System• Elutra System• Extracorporeal Photopheresis• Trima Accel System• Leukoreduction• Managing anemia, bleeding and othercomplications from chemotherapy or
graft-versus-host disease© Terumo Corporation

Dec 12, 2016

4/17

Solutions to Drive Standards of Care
Autoimmune Disorders

Autoimmune Disorders• Spectra Optia System• Providing treatment and therapeutic
options for Guillain-Barré syndrome
and myasthenia gravis• Extracorporeal Photopheresis• Quantum System• Elutra System• Shifting immune system response fromattack to heal with therapeutic plasma
exchange and stem cell therapies© Terumo Corporation

Dec 12, 2016

5/17

Solutions to Drive Standards of Care
Hematology

Hematology• Hemostasis management solutions fortransfusion medicine and trauma,including pathogen reduction, freezedried plasma and cold-stored platelets• Trima Accel System• TACSI, Reveos Systems• Mirasol PRT System• Setting the standard for global bloodsafety, effective bleeding treatments andbleeding prevention with established andin-development hemostasis solutions• Spectra Optia System• Freeze-Dried Plasma• Cold-Stored Platelets© Terumo Corporation

Dec 12, 2016

6/17

Solutions to Drive Standards of CareRegenerative Medicine

Regenerative Medicine• Enabling stem cell research andcommercialization of breakthroughtherapies—mesenchymal stem cells
and CAR T-cells• Spectra Optia System• Quantum System• Elutra System• Personalized, self-healing medicine
and pain management; initial focus
on orthopedics and sports enables
breakthroughs in cardiology, trauma
and immune diseases• Harvest BMAC System• Harvest Platelet Concentrate
System© Terumo Corporation

Dec 12, 2016

7/17

Global Market Leader Position
Growth Opportunities for Three Business Segments

Blood Centers

Therapeutic Systems

Advancing blood therapies toDelivering higher economic
and clinical value with strategic bring more treatment options
to patients
supply chain solutions© Terumo Corporation

Cell Processing

Enabling cellular therapies
that may fundamentally
improve outcomes

Dec 12, 20168/17

Blood Centers
Leverage Our Market Leadership
Delivering higher economic and clinical valuewith strategic supply chain solutions

Created an $870M+ apheresis collections market#1 Apheresis collections (50%+ share) Informatics/software forblood center management
 Whole blood automation (WBA)#2 Pathogen reduction technologies
 Whole blood bags

© Terumo Corporation

Mid-Single-Digit

GrowthTGBM Worldwide Sales
FY16 to FY21

Dec 12, 20169/17

Blood Centers
Protect and Grow
Improve the Whole Blood Automation (WBA) cost structure
Optimize apheresis collections
Drive global blood safety initiatives
Develop clinical solutions for hemostasis management© Terumo Corporation

Dec 12, 2016

10/17

Therapeutic Systems
Advance Therapeutic Apheresis
Advancing blood therapies to bring more treatment
options to patients

Created and set the industry standard fortherapeutic apheresis devices
plasma exchange#1  Therapeutic(50%+ share)

High-Single-Digit

GrowthTGBM Worldwide Sales
FY16 to FY21

 Cell collections (87% share)© Terumo Corporation

Dec 12, 2016

11/17

Therapeutic Systems
Extend Our Leadership
Drive adoption of therapeutic plasma exchange (TPE) for thetreatment of autoimmune diseases
Defend our leadership position in therapeutic apheresis© Terumo Corporation

Dec 12, 201612/17

Cell Processing
Unlocking the Potential of Cells
Enabling cellular therapies that may
fundamentally improve outcomes

Creating the market for the first automatedsystem designed to grow adherent andsuspension cells in a closed environment#1

Double Digit

GrowthTGBM Worldwide Sales
FY16 to FY21

 Point-of-Care injectable cell therapies
 Sterile connection devices
 Driving to be the first to market with endto-end immunotherapy solutions© Terumo Corporation

Dec 12, 201613/17

Cell Processing
Extend and Diversify Cell Therapy Technologies
Protect and Grow Point-of-Care Cell Therapies

Create solutions for regenerative medicine
Accelerate growth in Point-of-Care Cell Therapies© Terumo Corporation

Dec 12, 2016

14/17

Global Innovation and Development
24/7 for Maximum Internal Efficiency; Combined with 30 Global Partners
Fujinomiya
Filters Engineering
Plastics Engineering

Larne
Fluids Engineering
Process Engineering

Long Thanh
Process Engineering

Leuven/Zaventem
Hardware Engineering
Software Engineering

Lakewood
Hardware Engineering
Software Engineering
Plastics Engineering
Blood Science V&V
Process Engineering

Trivandrum
Hardware Engineering
Plastics Engineering
Blood Science V&V

V&V = verification and validation

Outsourcing Partners
Terumo BCT 24/7 global innovation and development
footprint with 30 external global partners© Terumo CorporationDec 12, 2016

15/17

Sales and Operating Income Target toward FY21
SalesOperating Income

Return to growth

Achieve profit growth fasterthan revenue growthMid-single-digit
growthHigh-single-digit
growthPlan FX rate: USD=105 JPU, EUR=115 JPY*Adjusted operating income (IFRS)
Adjusted items: Intangible asset derived from acquisition, one-time acquisition expense, impairment, gain/loss from sales of stocks and others

FY10

FY16

FY21

FY10

© Terumo Corporation

FY16

FY21
Dec 12, 2016

16/17

Every Second of Every Day
We Are Saving Lives HereContributing to Society through Healthcare© Terumo Corporation

Dec 12, 201617/17

© Terumo Corporation

Disclaimer
The information that Terumo discloses and the forward-looking statements
including financial projections are based upon our assumptions using
information available to us at the time and are not intended to be guarantees of
future events or performance. Accordingly, it should be noted that actual
results may differ from those forecasts on projections due to various factors.
Factors affecting actual results include, but are not limited to, changes in
economic conditions surrounding Terumo, fluctuations of foreign exchange
rates, and state of the competition.
The market share information in this presentation is partly derived from ourown independent research.

© Terumo Corporation